Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,054 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sensitive Skin Clear all

Conditions: Healthy, Dermatitis, Atopic
Interventions: LY3844583, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Dermatitis, Atopic
Interventions: Bermekimab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Indianapolis, Indiana • Chesterfield, Michigan • Tulsa, Oklahoma + 2 more

Conditions: Chronic Urticaria
Interventions: Omalizumab; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Placebos; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 29
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 25 more

Conditions: Eczema, Atopic Dermatitis
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 50 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Vitiligo, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa (HS)
Interventions: Not listed
Lead sponsor: Target PharmaSolutions, Inc.; Industry
Eligibility: Not listed
Enrollment: 2,000,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2041
U.S. locations: 1
States / cities: New York, New York

Conditions: Atopic Dermatitis
Interventions: Galvokimig, Placebo; Biological · Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: Oceanside, California • Santa Monica, California • Boca Raton, Florida + 14 more

Conditions: Allergic Contact Dermatitis
Interventions: Patch testing; Diagnostic Test
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years to 89 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sharp's Syndrome
Interventions: Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs, Lipoaspiration; Other
Lead sponsor: Arkansas Heart Hospital; Other
Eligibility: 18 Years to 99 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Atopic Dermatitis
Interventions: Itch CBT; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 8 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Vasculitis, Systemic Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis, Eosinophilic Granulomatous Vasculitis, Temporal Arteritis, Giant Cell Arteritis, Granulomatosis With Polyangiitis, Wegener Granulomatosis, Henoch Schonlein Purpura, IgA Vasculitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Urticarial Vasculitis
Interventions: Online Questionnaire; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: Not listed
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema
Interventions: Crisaborole 2% Top Oint, Skin Microbiome Swabs; Drug · Genetic
Lead sponsor: University of California, Irvine; Other
Eligibility: 2 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Irvine, California

Conditions: Atopic Dermatitis
Interventions: tacrolimus ointment; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 2 Years to 15 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Atopic Dermatitis, Eczema
Interventions: Dilute vinegar (acetic acid), Dilute bleach; Other
Lead sponsor: University of Arizona; Other
Eligibility: 5 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Atopic Dermatitis
Interventions: KT-621, Placebo; Drug · Other
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 12 more

Conditions: Hereditary Angioedema
Interventions: rhC1INH, Placebo (Saline); Drug
Lead sponsor: Pharming Technologies B.V.; Industry
Eligibility: 13 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 15
States / cities: Scottsdale, Arizona • Granada Hills, California • Los Angeles, California + 12 more

Conditions: Cutaneous Leishmaniasis
Interventions: Leishmania tropica Skin Test Antigen (LtSTA), Leishmania tropica Skin Test Antigen Placebo (Placebo); Biological
Lead sponsor: Nielsen BioSciences, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis, AD
Interventions: Placebo, IMG-007; Drug
Lead sponsor: Inmagene LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Northridge, California • Valencia, California • Miami, Florida + 6 more

Conditions: Atopic Dermatitis
Interventions: GHZ339, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 24
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 20 more

Conditions: Atopic Dermatitis
Interventions: LEO 138559, LEO 138559 Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Urticaria
Interventions: GDC-0853; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 10
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 7 more

Conditions: Atopic Dermatitis Eczema, Atopic Dermatitis, Eczema
Interventions: Team-Based Connected Health (TCH); Other
Lead sponsor: University of Southern California; Other
Eligibility: 1 Year and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Type I Hypersensitivity
Interventions: RagweedMATAMPL; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 4
States / cities: Novi, Michigan • Minneapolis, Minnesota • Asheville, North Carolina + 1 more

Conditions: Atopic Dermatitis
Interventions: ruxolitinib cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 30
States / cities: Fountain Valley, California • Long Beach, California • Washington D.C., District of Columbia + 26 more

Search by objective public record fields.

A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis

A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

Sodium in the Skin and Atopic Dermatitis

An Observational Study of Patients With Dermatologic Disease

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

Patient Experience and Quality of Patch Testing on the Legs vs Back

Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic Lupus Erythematosus or Sharp's Syndrome

Brief Cognitive Behavioral Therapy to Treat Itch Rumination "Itch CBT" in Eczema

Journey of Patients With Vasculitis From First Symptom to Diagnosis

Characterizing Skin Microbiome Change in Atopic Dermatitis

Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit

Evaluating the Effect of Bathing Additives in Atopic Dermatitis

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks

Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study

Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis

Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test

The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.